The COVID-19 pandemic has disrupted every aspect of medical care, including screeningprograms and preventive medical care . Organized FIT-based colorectal cancer screeningprograms make no exception, since their efficacy depends on a multi-tiered series ofinterventions that were hampered by the pandemic at multiple levels. In detail, the firstlevel of intervention, namely population based FIT tests distributed to the population,has seen a dramatic decrease of number of tests performed for both organizational reasons(i.e. less personnel deployed to testing sites) and for failure to present fecal samplesfrom patients for fear of contagion or impossibility to reach the drop-off sites forstate-imposed limitations. Secondly, the referral of FIT positive patients to subsequentcolonoscopy was stopped or delayed since endoscopy services have been undergoing onlyemergent and urgent procedures. Thirdly, patients diagnosed with advanced neoplasia orcancer have seen their endoscopic or surgical removal procedures delayed or canceled .Regarding post-FIT colonoscopy workup, European Screening Guidelines recommend a 30-daymaximum span between a positive FIT test and subsequent colonoscopy. It is well knownthat any delay in post-FIT+ colonoscopy results in an increase in advanced neoplasia andcolorectal cancer, that reaches dramatic levels after 6 months .Our purpose is to develop and validate, using the quantitative level of faecal hemoglobinfound in FIT, a simple scoring system to effectively sub-stratify CRC risk of FITpositive patients.